STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
STAT News · LC · trust 36/100
Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.
Read the original at STAT News →
Open in TruthVane →